Diuretics are still the preferred initial drugs for high blood pressure

Cleveland Clinic Journal of Medicine

Volumn 70, Issue 3, 2003, Pages 263-269

  Vidt, Donald G ^a  

^a LERNER RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMLODIPINE; AMLODIPINE BESYLATE; ANTIHYPERTENSIVE AGENT; ATENOLOL; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BETAXOLOL; BISOPROLOL; CALCIUM CHANNEL AFFECTING AGENT; CHLORTALIDONE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DOXAZOSIN; LISINOPRIL; METOPROLOL; NADOLOL; PRAVASTATIN; PROPRANOLOL; THIAZIDE DIURETIC AGENT; TIMOLOL; DIURETIC AGENT;

ARTICLE; CLINICAL TRIAL; COMORBIDITY; CONGESTIVE HEART FAILURE; DIABETES MELLITUS; DISEASE CONTROL; DRUG COST; HUMAN; HYPERCHOLESTEROLEMIA; HYPERGLYCEMIA; HYPERTENSION; HYPOKALEMIA; TREATMENT OUTCOME; AGED; BLOOD PRESSURE MEASUREMENT; COMPARATIVE STUDY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; DRUG ADMINISTRATION; FEMALE; FOLLOW UP; HOSPITALIZATION; MALE; MIDDLE AGED; PATIENT COMPLIANCE; PROBABILITY; RANDOMIZED CONTROLLED TRIAL; RISK ASSESSMENT;

AGED; AMLODIPINE; ANTIHYPERTENSIVE AGENTS; BLOOD PRESSURE DETERMINATION; CHLORTHALIDONE; DIURETICS; DOSE-RESPONSE RELATIONSHIP, DRUG; DOXAZOSIN; DRUG ADMINISTRATION SCHEDULE; FEMALE; FOLLOW-UP STUDIES; HUMANS; HYPERTENSION; LISINOPRIL; MALE; MIDDLE AGED; PATIENT COMPLIANCE; PROBABILITY; RISK ASSESSMENT; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME;

EID: 0037368286     PISSN: 08911150     EISSN: None     Source Type: Journal    
DOI: 10.3949/ccjm.70.3.263     Document Type: Article

References (10)

1. The ALLHAT officers and coordinators for the ALLHAT Collaborative Research Group. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic. The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA 2002; 288:2981-2997.
2. Davis BR, Cutler JA, Gordon D, et al, for the ALLHAT Research Group. Rationale and design of the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). Am J Hypertens 1996; 9:342-360.
3. The ALLHAT officers and coordinators for the ALLHAT Collaborative Research Group. The Antihypertensive and Lipid-Lowering Treatment to Prevent heart Attack Trial (ALLHAT). Major cardiovascular events in hypertensive patients randomized to doxazosin vs chlorthalidone. JAMA 2000; 283:1967-1975.
4. Vidt DG. Alpha-blockers and congestive heart failure: Early termination of an arm of the ALLHAT trial. Cleve Clin J Med 2000; 67:429-433.
5. The ALLHAT officers and coordinators for the ALLHAT Collaborative Research Group. Major outcomes in moderately hypercholesterolemic, hypertensive patients randomized to pravastatin vs usual care. The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT-LLT). JAMA 2002; 288:2998-3007.
6. The sixth report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Arch Intern Med 1997; 157:2413-1446.
7. The Heart Outcomes Prevention Evaluation Study Investigators. Effects of an angiotensin-converting enzyme inhibitor, ramipril, on death from cardiovascular causes, myocardial infarction, and stroke in high-risk patients. N Engl J Med 2000; 342:145-153.
8. Hansson L, Lindholm LH, Niskanen L, et al. Effect of angiotensin-converting enzyme inhibition compared with conventional therapy on cardiovascular morbidity and mortality in hypertension: the Captopril Prevention Project (CAPP) randomised trial. Lancet 1999; 353:611-616.
9. Psaty BM, Smith NL, Siscovick DS, et al. Health outcomes associated with antihypertensive therapies used as first-line agents: a systematic review and meta-analysis. JAMA 1997; 277:739-745.
10. Agodoa LY, Appel L, Bakris GL, et al. Effect of ramipril vs amlodipine on renal outcomes in hypertensive nephrosclerosis. A randomized controlled trial. JAMA 2001; 285:2719-2728.